Search

Your search keyword '"Jaurand, Marie-Claude"' showing total 44 results
Start Over Author "Jaurand, Marie-Claude" Publication Year Range Last 10 years
44 results on '"Jaurand, Marie-Claude"'

4. Evaluating the mechanistic evidence and key data gaps in assessing the potential carcinogenicity of carbon nanotubes and nanofibers in humans

Author

Kuempel, Eileen D, Jaurand, Marie-Claude, Møller, Peter, Morimoto, Yasuo, Kobayashi, Norihiro, Pinkerton, Kent E, Sargent, Linda M, Vermeulen, Roel CH, Fubini, Bice, and Kane, Agnes B

Subjects
Medical Biotechnology, Biomedical and Clinical Sciences, Prevention, Bioengineering, Cancer, Nanotechnology, Animals, Carcinogenicity Tests, Humans, Nanofibers, Nanotubes, Carbon, Cancer mechanisms, carbon nanofibers, carbon nanotubes, cell proliferation, fibrosis, genotoxicity, inflammation, lung cancer, mesothelioma, particle retention, pulmonary, translocation, Pharmacology and Pharmaceutical Sciences, Toxicology, Pharmacology and pharmaceutical sciences
Abstract

In an evaluation of carbon nanotubes (CNTs) for the IARC Monograph 111, the Mechanisms Subgroup was tasked with assessing the strength of evidence on the potential carcinogenicity of CNTs in humans. The mechanistic evidence was considered to be not strong enough to alter the evaluations based on the animal data. In this paper, we provide an extended, in-depth examination of the in vivo and in vitro experimental studies according to current hypotheses on the carcinogenicity of inhaled particles and fibers. We cite additional studies of CNTs that were not available at the time of the IARC meeting in October 2014, and extend our evaluation to include carbon nanofibers (CNFs). Finally, we identify key data gaps and suggest research needs to reduce uncertainty. The focus of this review is on the cancer risk to workers exposed to airborne CNT or CNF during the production and use of these materials. The findings of this review, in general, affirm those of the original evaluation on the inadequate or limited evidence of carcinogenicity for most types of CNTs and CNFs at this time, and possible carcinogenicity of one type of CNT (MWCNT-7). The key evidence gaps to be filled by research include: investigation of possible associations between in vitro and early-stage in vivo events that may be predictive of lung cancer or mesothelioma, and systematic analysis of dose-response relationships across materials, including evaluation of the influence of physico-chemical properties and experimental factors on the observation of nonmalignant and malignant endpoints.

Published
2017

5. Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma

Author

Meiller, Clément, Montagne, François, Hirsch, Theo Z., Caruso, Stefano, de Wolf, Julien, Bayard, Quentin, Assié, Jean-Baptiste, Meunier, Léa, Blum, Yuna, Quetel, Lisa, Gibault, Laure, Pintilie, Ecaterina, Badoual, Cécile, Humez, Sarah, Galateau-Sallé, Françoise, Copin, Marie-Christine, Letouzé, Eric, Scherpereel, Arnaud, Zucman-Rossi, Jessica, Le Pimpec-Barthes, Françoise, Jaurand, Marie-Claude, and Jean, Didier

Published
2021
Full Text
View/download PDF

7. Supplementary Material and Methods from Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma

Author

Tranchant, Robin, primary, Quetel, Lisa, primary, Tallet, Anne, primary, Meiller, Clement, primary, Renier, Annie, primary, de Koning, Leanne, primary, de Reynies, Aurelien, primary, Le Pimpec-Barthes, Francoise, primary, Zucman-Rossi, Jessica, primary, Jaurand, Marie-Claude, primary, and Jean, Didier, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Table 2 from Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition

Author

de Reyniès, Aurélien, primary, Jaurand, Marie-Claude, primary, Renier, Annie, primary, Couchy, Gabrielle, primary, Hysi, Ilir, primary, Elarouci, Nabila, primary, Galateau-Sallé, Françoise, primary, Copin, Marie-Christine, primary, Hofman, Paul, primary, Cazes, Aurélie, primary, Andujar, Pascal, primary, Imbeaud, Sandrine, primary, Petel, Fabien, primary, Pairon, Jean-Claude, primary, Le Pimpec-Barthes, Francoise, primary, Zucman-Rossi, Jessica, primary, and Jean, Didier, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Table 3 from Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition

Author

de Reyniès, Aurélien, primary, Jaurand, Marie-Claude, primary, Renier, Annie, primary, Couchy, Gabrielle, primary, Hysi, Ilir, primary, Elarouci, Nabila, primary, Galateau-Sallé, Françoise, primary, Copin, Marie-Christine, primary, Hofman, Paul, primary, Cazes, Aurélie, primary, Andujar, Pascal, primary, Imbeaud, Sandrine, primary, Petel, Fabien, primary, Pairon, Jean-Claude, primary, Le Pimpec-Barthes, Francoise, primary, Zucman-Rossi, Jessica, primary, and Jean, Didier, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Table S4 from Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition

Author

de Reyniès, Aurélien, primary, Jaurand, Marie-Claude, primary, Renier, Annie, primary, Couchy, Gabrielle, primary, Hysi, Ilir, primary, Elarouci, Nabila, primary, Galateau-Sallé, Françoise, primary, Copin, Marie-Christine, primary, Hofman, Paul, primary, Cazes, Aurélie, primary, Andujar, Pascal, primary, Imbeaud, Sandrine, primary, Petel, Fabien, primary, Pairon, Jean-Claude, primary, Le Pimpec-Barthes, Francoise, primary, Zucman-Rossi, Jessica, primary, and Jean, Didier, primary

Published
2023
Full Text
View/download PDF

12. Legends of Supplementary Figures from Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma

Author

Tranchant, Robin, primary, Quetel, Lisa, primary, Tallet, Anne, primary, Meiller, Clement, primary, Renier, Annie, primary, de Koning, Leanne, primary, de Reynies, Aurelien, primary, Le Pimpec-Barthes, Francoise, primary, Zucman-Rossi, Jessica, primary, Jaurand, Marie-Claude, primary, and Jean, Didier, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Table 1 from Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition

Author

de Reyniès, Aurélien, primary, Jaurand, Marie-Claude, primary, Renier, Annie, primary, Couchy, Gabrielle, primary, Hysi, Ilir, primary, Elarouci, Nabila, primary, Galateau-Sallé, Françoise, primary, Copin, Marie-Christine, primary, Hofman, Paul, primary, Cazes, Aurélie, primary, Andujar, Pascal, primary, Imbeaud, Sandrine, primary, Petel, Fabien, primary, Pairon, Jean-Claude, primary, Le Pimpec-Barthes, Francoise, primary, Zucman-Rossi, Jessica, primary, and Jean, Didier, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figures from Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition

Author

de Reyniès, Aurélien, primary, Jaurand, Marie-Claude, primary, Renier, Annie, primary, Couchy, Gabrielle, primary, Hysi, Ilir, primary, Elarouci, Nabila, primary, Galateau-Sallé, Françoise, primary, Copin, Marie-Christine, primary, Hofman, Paul, primary, Cazes, Aurélie, primary, Andujar, Pascal, primary, Imbeaud, Sandrine, primary, Petel, Fabien, primary, Pairon, Jean-Claude, primary, Le Pimpec-Barthes, Francoise, primary, Zucman-Rossi, Jessica, primary, and Jean, Didier, primary

Published
2023
Full Text
View/download PDF

15. Legends of Supplementary Figures and Tables from Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition

Author

de Reyniès, Aurélien, primary, Jaurand, Marie-Claude, primary, Renier, Annie, primary, Couchy, Gabrielle, primary, Hysi, Ilir, primary, Elarouci, Nabila, primary, Galateau-Sallé, Françoise, primary, Copin, Marie-Christine, primary, Hofman, Paul, primary, Cazes, Aurélie, primary, Andujar, Pascal, primary, Imbeaud, Sandrine, primary, Petel, Fabien, primary, Pairon, Jean-Claude, primary, Le Pimpec-Barthes, Francoise, primary, Zucman-Rossi, Jessica, primary, and Jean, Didier, primary

Published
2023
Full Text
View/download PDF

16. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications

Author

Blum, Yuna, Meiller, Clément, Quetel, Lisa, Elarouci, Nabila, Ayadi, Mira, Tashtanbaeva, Danisa, Armenoult, Lucile, Montagne, François, Tranchant, Robin, Renier, Annie, de Koning, Leanne, Copin, Marie-Christine, Hofman, Paul, Hofman, Véronique, Porte, Henri, Le Pimpec-Barthes, Françoise, Zucman-Rossi, Jessica, Jaurand, Marie-Claude, de Reyniès, Aurélien, and Jean, Didier

Published
2019
Full Text
View/download PDF

17. Fibres courtes d’amiante et autres particules minérales allongées de moins de 5 micromètres de longueur - Mise à jour des données sanitaires et d’exposition

Author

Paris, Christophe, Billon-Galland, Marie-Annick, Brochard, Patrick, Clin-Godard, Benedicte, Eypert-Blaison, Céline, Jaurand, Marie-Claude, Joubert, Olivier, Luce, Danièle, Martinon, Laurent, Pairon, Jean-Claude, Trouiller, Bénédicte, Durand, Emmanuelle, Andrianjafimasy, Miora, Paillat, Amandine, Épidémiologie en Santé au Travail et Ergonomie (IRSET-ESTER), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Bordeaux (UB), Service de médecine interne [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Institut National de la Recherche Scientifique [Québec] (INRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Jean Lamour (IJL), Institut de Chimie du CNRS (INC)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Amiante Fibres Particules (LAFP), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut National de l'Environnement Industriel et des Risques (INERIS), Direction de l'Evaluation des Risques (DER), Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), Anses, and Druesne, Christine

Subjects
[SDV] Life Sciences [q-bio], health effect, fibres courtes d’amiante, effets sanitaires, exposure, particules minérales allongées, [SDV]Life Sciences [q-bio], particules minérales allongées d’intérêt, Asbestos, short asbestos fibers, Amiante, exposition, elongated mineral particles
Abstract

Citation suggérée : Anses. (2022). Fibres courtes d’amiante et autres particules minérales allongées de moins de 5 micromètres de longueur. Mises à jour des données sanitaires et d’exposition. (saisine 2019-SA-0044). Maisons-Alfort : Anses, 124 p.; L’Anses a été saisie en mars 2019 par la Direction Générale de la Santé (DGS) pour réaliser une mise à jour des données sanitaires (épidémiologiques et toxicologiques) et d’exposition aux fibres courtes d’amiante (FCA). Cette demande fait suite à la publication en 2009 d’une première expertise sur le sujet, concluant, sur la base des données disponibles, qu’il n’était pas possible d’écarter avec certitude l’existence de propriétés cancérogènes des FCA (Anses, 2009a). Dans l’hypothèse d’une toxicité des FCA, elle serait certainement inférieure à celle des fibres longues. Les données acquises lors de cette expertise concernant la distribution granulométrique des fibres d’amiante, que ce soit pour l’environnement général, professionnel ou à proximité d’affleurements naturels, soulignent la prépondérance des FCA associées à des concentrations élevées. Ces conclusions étaient fondées sur une analyse documentaireapprofondie et une collecte de données sur la distribution granulométrique des fibres d’amiante dans divers environnements, tels que les espaces intérieurs et extérieurs, et dans le milieu professionnel. Depuis la publication de ce rapport, la toxicité des FCA est encore en discussion dans la communauté scientifique et de nouvelles études visant à renforcer les connaissances ont été conduites. Sur le volet « exposition » en particulier, la DGS a commandé en 2011 au Laboratoire Amiante Fibres et Particules (LAFP) de la Ville de Paris une étude dont l’objectif était d’évaluer les empoussièrements en fibres d’amiante générés lors de la mise en œuvre de nettoyage de dalles de sol en vinyle amiante (DVA) dans un collègeet un hôpital. Des niveaux significatifs ayant été relevés sur certains points de mesure, une étude complémentaire a été engagée pour confirmer les résultats dans d’autres locaux. Les concentrations en FCA mesurées dans cette seconde étude sont moins élevées et hétérogènes (entre 1 et 75 FCA/L), sans qu’aucune corrélation avec des fibres d’amiante de longueur supérieure à 5 μm n’ait pu être établie.

Published
2022

20. Abstract 3128: Spatial intra-tumor molecular heterogeneity in malignant pleural mesothelioma

Author

Meiller, Clément, primary, Montagne, François, additional, Hirsch, Théo Z., additional, Caruso, Stefano, additional, de Wolf, Julien, additional, Bayard, Quentin, additional, Assié, Jean-Baptiste, additional, Meunier, Léa, additional, Blum, Yuna, additional, Quetel, Lisa, additional, Gibault, Laure, additional, Pintilie, Ecaterina, additional, Badoual, Cécile, additional, Copin, Marie-Christine, additional, Letouzé, Eric, additional, Scherpereel, Arnaud, additional, Zucman-Rossi, Jessica, additional, Pimpec-Barthes, Françoise Le, additional, Jaurand, Marie-Claude, additional, and Jean, Didier, additional

Published
2021
Full Text
View/download PDF

21. Additional file 2 of Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma

Author

Meiller, Clément, Montagne, François, Hirsch, Theo Z., Caruso, Stefano, de Wolf, Julien, Bayard, Quentin, Assié, Jean-Baptiste, Meunier, Léa, Blum, Yuna, Quetel, Lisa, Gibault, Laure, Pintilie, Ecaterina, Badoual, Cécile, Humez, Sarah, Galateau-Sallé, Françoise, Copin, Marie-Christine, Letouzé, Eric, Scherpereel, Arnaud, Zucman-Rossi, Jessica, Le Pimpec-Barthes, Françoise, Jaurand, Marie-Claude, and Jean, Didier

Abstract

Additional file 2: Figure S1. Positron emission tomography (PET) scans of the two patients with biopsies performed on highest metabolite sites. Figure S2. Frequencies of BAP1 and NF2 variants in the fresh tumor sample used to generate the MPM_83 primary cell line. Figure S3. Cancer cell fraction in paired MPM samples. Figure S4. Pangenomic copy number variation profile determined by DNAcopy. Figure S5. Pangenomic copy number variation profile determined by FACET. Figure S6. Fusion transcripts identified by RNA-seq. Figure S7. Unsupervised clustering of MPM tumor samples based on gene expression profiles. Figure S8. Differentially expressed genes between paired tumor samples. Figure S9. Single sample Gene Set Enrichment Analysis (ssGSEA) for pathways related to cell adhesion and extracellular matrix. Figure S10. Epigenetic intra-tumor heterogeneity. Figure S11. Differential infiltration of stromal and immune cell populations. Figure S12. Distribution of immune and stromal populations among paired tumor samples. Figure S13. Single sample Gene Set Enrichment Analysis (ssGSEA) for pathways related to immune cell infiltration. Figure S14. Immunohistochemical staining of tumor-infiltrating T and B cells in patients with paired tumor samples switching from a cold to a hot immune profile.

Published
2021
Full Text
View/download PDF

22. Genetic alterations of malignant pleural mesothelioma: association to tumor heterogeneity and overall survival Author names

Author

Quetel, Lisa, Meiller, Clément, Assié, Jean-Baptiste, Blum, Yuna, Imbeaud, Sandrine, Montagne, François, Tranchant, Robin, de Wolf, Julien, Caruso, Stefano, Copin, Marie-Christine, Hofman, Véronique, Gibault, Laure, Badoual, Cecile, Pintilie, Ecaterina, Hofman, Paul, Monnet, Isabelle, Scherpereel, Arnaud, Le Pimpec-Barthes, Françoise, Zucman-Rossi, Jessica, Jaurand, Marie-Claude, Jean, Didier, Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), (le programme) Cartes d'identité des tumeurs (CIT), Ligue Nationales Contre le Cancer (LNCC), Genexpress, Génomique Fonctionnelle et Biologie Systémique pour la Santé, Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Institut de Pathologie [CHU Lille], Pôle de Biologie Pathologie Génétique [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université de Lille, Laboratoire de Pathologie Clinique et Expérimentale. Hôpital Pasteur [Nice], Hôpital Pasteur [Nice] (CHU), FHU OncoAge - Pathologies liées à l’âge [CHU Nice] (OncoAge), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)-Institut de Pharmacologie Moléculaire et Cellulaire [UNIV Côte d'Azur] (UPMC), Service d'Anatomo-cytopathologie [Hôpital Européen Georges Pompidou - APHP], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Service de Chirurgie Thoracique [CHRU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Pneumologie et de Pathologie Professionnelle [CHI Créteil], CHI Créteil, Réseau National Expert pour le Mésothéliome Pleural Malin [Lille] (MESOCLIN), Pneumologie et Oncologie Thoracique [CHRU de Lille], PRES Université Lille Nord de France-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Hôpital Albert Calmette-Faculté de Médecine Henri Warembourg, Service de Chirurgie Thoracique (Hôpital Européen Georges Pompidou [APHP] HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), This work was supported by Inserm, the Ligue Contre le Cancer (Ile de France committee and national program Cartes d’Identité des Tumeurs (CIT)), the Fondation ARC pour la recherche sur le cancer, Hadassah France, and the Chancellerie des Universités de Paris (Legs POIX). LQ, JBA, FM and JdW were supported by grants from Cancéropôle Région Île-de France, from Fondation pour la Recherche Médicale (FRM), from the Institut thématique multi-organismes (ITMO) Cancer (Plan Cancer 2014-2019) and from the Fondation ARC, respectively. JdW and FM were also supported by grant of the Société Française de Chirurgie Thoracique et Cardio-Vasculaire (SFCTCV). The Inserm research unit is supported by the Labex OncoImmunology (investissement d’avenir), Coup d’Elan de la Fondation Bettencourt-Shueller, the SIRIC CARPEM, the Institut thématique multi-organismes (ITMO) Cancer (Plan Cancer 2014-2019) and Cancéropôle Île-de-France., École Pratique des Hautes Études (EPHE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Pharmacologie Moléculaire et Cellulaire [UNIV Côte d'Azur] (UPMC)-Université Côte d'Azur (UCA), PRES Université Lille Nord de France-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Faculté de Médecine Henri Warembourg - Université de Lille-Hôpital Albert Calmette, and Jean, Didier

Subjects
tumor molecular classification, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, [SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics, [SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, Thoracic cancer, [SDV.CAN] Life Sciences [q-bio]/Cancer, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], tumor heterogeneity, [SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], prognosis, [SDV.BC] Life Sciences [q-bio]/Cellular Biology, gene mutations
Abstract

International audience; Development of precision medicine for malignant pleural mesothelioma (MPM) requires a deep knowledge of tumor heterogeneity. Histologic and molecular classifications and histo-molecular gradients have been proposed to describe heterogeneity, but a deeper understanding of gene mutations in the context of MPM heterogeneity is required and the associations between mutations and clinical data need to be refined. We characterized genetic alterations on one of the largest MPM series (266 tumor samples), well-annotated with histologic, molecular and clinical data of patients. Targeted next generation sequencing was performed focusing on the major MPM mutated genes and the TERT promoter. Molecular heterogeneity was characterized using predictors allowing classification of each tumor into the previously described molecular subtypes and the determination of the proportion of epithelioïd-like and sarcomatoïd-like components (E/S.scores). The mutation frequencies are consistent with literature data, but this study emphasized that TERT promoter, not considered by previous large sequencing studies, was the third locus most affected by mutations in MPM. Mutations in TERT promoter, NF2 and LATS2 were more frequent in non-epithelioid MPM and positively associated to the S.score. BAP1, NF2, TERT promoter, TP53 and SETD2 mutations were enriched in some molecular subtypes. NF2 mutation rate was higher in asbestos unexposed patient. TERT promoter, NF2 and TP53 mutations were associated with a poorer overall survival. Our findings lead to a better characterization of MPM heterogeneity by identifying new significant associations between mutational status and histologic and molecular heterogeneity. Strikingly, we highlight the strong association between new mutations and overall survival.

Published
2020

23. Effets sanitaires de la silice cristalline–Expertise collective Anses

Author

Paris, Christophe, primary, Fourneau, Clémence, additional, Bernaudin, Jean-François, additional, Brochard, Patrick, additional, Cavalin, Catherine, additional, Dewitte, Jean-Dominique, additional, Fubini, Bice, additional, Hédouin-langlet, Catherine, additional, Jaurand, Marie-Claude, additional, Jego, Patrick, additional, Rousset, Davy, additional, and Paillat, Amandine, additional

Published
2020
Full Text
View/download PDF

24. Analyse de revues épidémiologiques et toxicologiques (R-Amstar adaptée) - expertise Anses

Author

Fourneau, Clémence, primary, Bernaudin, Jean-François, additional, Brochard, Patrick, additional, Cavalin, Catherine, additional, Dewitte, Jean-Dominique, additional, Fubini, Bice, additional, Hedouin-Langlet, Catherine, additional, Jaurand, Marie-Claude, additional, Jego, Patrick, additional, Paillat, Amandine, additional, Rousset, Davy, additional, and Paris, Christophe, additional

Published
2020
Full Text
View/download PDF

25. Caractérisation des expositions professionnelles à la silice cristalline–expertise Anses

Author

Paillat, Amandine, primary, Bernaudin, Jean-François, additional, Brochard, Patrick, additional, Cavalin, Catherine, additional, Dewitte, Jean-Dominique, additional, Fourneau, Clémence, additional, Fubini, Bice, additional, Hédouin-langlet, Catherine, additional, Jaurand, Marie-Claude, additional, Jego, Patrick, additional, Rousset, Davy, additional, and Paris, Christophe, additional

Published
2020
Full Text
View/download PDF

27. Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival

Author

Quetel, Lisa, primary, Meiller, Clément, additional, Assié, Jean‐Baptiste, additional, Blum, Yuna, additional, Imbeaud, Sandrine, additional, Montagne, François, additional, Tranchant, Robin, additional, de Wolf, Julien, additional, Caruso, Stefano, additional, Copin, Marie‐Christine, additional, Hofman, Véronique, additional, Gibault, Laure, additional, Badoual, Cécile, additional, Pintilie, Ecaterina, additional, Hofman, Paul, additional, Monnet, Isabelle, additional, Scherpereel, Arnaud, additional, Le Pimpec‐Barthes, Françoise, additional, Zucman‐Rossi, Jessica, additional, Jaurand, Marie‐Claude, additional, and Jean, Didier, additional

Published
2020
Full Text
View/download PDF

28. Evaluation préclinique des médicaments inhibiteurs de CDK4/6 dans les mésothéliomes (lecture invitée)

Author

Roger, Pierre P., Paternot, Sabine, Raspé, Eric, Meiller, Clément, Jaurand, Marie Claude, Jean, Didier, Van Meerbeeck, Jan, Hylebos, Marieke, Pauwels, Patrick, Remmelink, Myriam, Pouliquen, Daniel, Blanquart, Christophe, Galateau-Salle, Françoise, De Vuyst, Paul, Berghmans, Thierry, Roger, Pierre P., Paternot, Sabine, Raspé, Eric, Meiller, Clément, Jaurand, Marie Claude, Jean, Didier, Van Meerbeeck, Jan, Hylebos, Marieke, Pauwels, Patrick, Remmelink, Myriam, Pouliquen, Daniel, Blanquart, Christophe, Galateau-Salle, Françoise, De Vuyst, Paul, and Berghmans, Thierry

Abstract

info:eu-repo/semantics/published

Published
2019

31. Some nanomaterials and some fibres

Author

Bateson, Thomas F., Drevvatne Bugge, Merete, Comba, Pietro, Debia, Maximilien, Dion, Chantal, Fubini, Bice, Guseva Canu, Irina, Jaurand, Marie-Claude, Kane, Agnes B., Kobayashi, Norihiro, Kuempel, Eileen D., Morgan, Daniel L., Morimoto, Yasuo, Møller, Peter, Pinkerton, Kent E., Sargent, Linda, Savolainen, Kai, Stayner, Leslie, Tsuda, Hiroyuki, Vermeulen, Roel, and Yu, Il Je

Published
2017

34. Evaluating the mechanistic evidence and key data gaps in assessing the potential carcinogenicity of carbon nanotubes and nanofibers in humans

Author

LS IRAS EEPI GRA (Gezh.risico-analyse), dIRAS RA-I&I RA, dIRAS RA-2, Kuempel, Eileen D, Jaurand, Marie-Claude, Møller, Peter, Morimoto, Yasuo, Kobayashi, Norihiro, Pinkerton, Kent E, Sargent, Linda M, Vermeulen, Roel C H, Fubini, Bice, Kane, Agnes B, LS IRAS EEPI GRA (Gezh.risico-analyse), dIRAS RA-I&I RA, dIRAS RA-2, Kuempel, Eileen D, Jaurand, Marie-Claude, Møller, Peter, Morimoto, Yasuo, Kobayashi, Norihiro, Pinkerton, Kent E, Sargent, Linda M, Vermeulen, Roel C H, Fubini, Bice, and Kane, Agnes B

Published
2017

35. Evaluating the mechanistic evidence and key data gaps in assessing the potential carcinogenicity of carbon nanotubes and nanofibers in humans

Author

Kuempel, Eileen D., Jaurand, Marie-Claude, Møller, Peter, Morimoto, Yasuo, Kobayashi, Norihiro, Pinkerton, Kent E., Sargent, Linda M., Vermeulen, Roel C. H., Fubini, Bice, Kane, Agnes B., Kuempel, Eileen D., Jaurand, Marie-Claude, Møller, Peter, Morimoto, Yasuo, Kobayashi, Norihiro, Pinkerton, Kent E., Sargent, Linda M., Vermeulen, Roel C. H., Fubini, Bice, and Kane, Agnes B.

Abstract

In an evaluation of carbon nanotubes (CNTs) for the IARC Monograph 111, the Mechanisms Subgroup was tasked with assessing the strength of evidence on the potential carcinogenicity of CNTs in humans. The mechanistic evidence was considered to be not strong enough to alter the evaluations based on the animal data. In this paper, we provide an extended, in-depth examination of the in vivo and in vitro experimental studies according to current hypotheses on the carcinogenicity of inhaled particles and fibers. We cite additional studies of CNTs that were not available at the time of the IARC meeting in October 2014, and extend our evaluation to include carbon nanofibers (CNFs). Finally, we identify key data gaps and suggest research needs to reduce uncertainty. The focus of this review is on the cancer risk to workers exposed to airborne CNT or CNF during the production and use of these materials. The findings of this review, in general, affirm those of the original evaluation on the inadequate or limited evidence of carcinogenicity for most types of CNTs and CNFs at this time, and possible carcinogenicity of one type of CNT (MWCNT-7). The key evidence gaps to be filled by research include: investigation of possible associations between in vitro and early-stage in vivo events that may be predictive of lung cancer or mesothelioma, and systematic analysis of dose–response relationships across materials, including evaluation of the influence of physico-chemical properties and experimental factors on the observation of nonmalignant and malignant endpoints.

Published
2017

36. Evaluating the mechanistic evidence and key data gaps in assessing the potential carcinogenicity of carbon nanotubes and nanofibers in humans

Author

Kuempel, Eileen D, Jaurand, Marie-Claude, Møller, Peter, Morimoto, Yasuo, Kobayashi, Norihiro, Pinkerton, Kent E, Sargent, Linda M, Vermeulen, Roel C H, Fubini, Bice, Kane, Agnes B, LS IRAS EEPI GRA (Gezh.risico-analyse), dIRAS RA-I&I RA, dIRAS RA-2, LS IRAS EEPI GRA (Gezh.risico-analyse), dIRAS RA-I&I RA, and dIRAS RA-2

Subjects
0301 basic medicine, pulmonary, Carcinogenicity Tests, particle retention, Nanofibers, translocation, Bioengineering, Nanotechnology, Carbon nanotube, Toxicology, Article, law.invention, nanotubes, 03 medical and health sciences, Animal data, Strength of evidence, Cancer mechanisms, law, Medicine, Animals, Humans, Limited evidence, Carcinogen, Cancer, carbon nanotubes, business.industry, Nanotubes, Carbon, Prevention, carbon, fibrosis, genotoxicity, Pharmacology and Pharmaceutical Sciences, Research needs, lung cancer, 030104 developmental biology, cell proliferation, inflammation, Nanofiber, mesothelioma, carbon nanofibers, Biochemical engineering, business, Cancer risk
Abstract

In an evaluation of carbon nanotubes (CNTs) for the IARC Monograph 111, the Mechanisms Subgroup was tasked with assessing the strength of evidence on the potential carcinogenicity of CNTs in humans. The mechanistic evidence was considered to be not strong enough to alter the evaluations based on the animal data. In this paper, we provide an extended, in-depth examination of the in vivo and in vitro experimental studies according to current hypotheses on the carcinogenicity of inhaled particles and fibers. We cite additional studies of CNTs that were not available at the time of the IARC meeting in October 2014, and extend our evaluation to include carbon nanofibers (CNFs). Finally, we identify key data gaps and suggest research needs to reduce uncertainty. The focus of this review is on the cancer risk to workers exposed to airborne CNT or CNF during the production and use of these materials. The findings of this review, in general, affirm those of the original evaluation on the inadequate or limited evidence of carcinogenicity for most types of CNTs and CNFs at this time, and possible carcinogenicity of one type of CNT (MWCNT-7). The key evidence gaps to be filled by research include: investigation of possible associations between in vitro and early-stage in vivo events that may be predictive of lung cancer or mesothelioma, and systematic analysis of dose–response relationships across materials, including evaluation of the influence of physico-chemical properties and experimental factors on the observation of nonmalignant and malignant endpoints.

Published
2016

42. Fragments de clivage d’amphiboles : identification, effets sanitaires et impact sur la réglementation

Author

Durand, Emmanuelle, primary, Boulanger, Guillaume, additional, Paillat, Amandine, additional, Brunet, Dominique, additional, Billon-Galland, Marie-Annick, additional, Brochard, Patrick, additional, Dion, Chantal, additional, Eypert-Blaison, Celine, additional, Jaurand, Marie-Claude, additional, Lahondère, Didier, additional, Luce, Daniele, additional, Martinon, Laurent, additional, and Michiels, Fabrice, additional

Published
2016
Full Text
View/download PDF

44. [Molecular heterogeneity of malignant pleural mesotheliomas].

Author

Tranchant R, Montagne F, Jaurand MC, and Jean D

Subjects
Asbestos toxicity, Carcinogens toxicity, Chromosome Aberrations, Epigenesis, Genetic, Humans, Lung Neoplasms classification, Lung Neoplasms etiology, Lung Neoplasms therapy, Mesothelioma classification, Mesothelioma etiology, Mesothelioma therapy, Mesothelioma, Malignant, Pleural Neoplasms classification, Pleural Neoplasms etiology, Pleural Neoplasms therapy, Prognosis, Transcription, Genetic, Lung Neoplasms genetics, Mesothelioma genetics, Pleural Neoplasms genetics
Abstract

Malignant pleural mesothelioma (MPM) is predominantly an occupational cancer, most often linked to asbestos exposure. Malignant pleural mesothelioma prognosis is poor with a short survival median, due to the aggressiveness of tumor cells and the weak efficiency of conventional anti-cancer therapies. Clinical, histological, and molecular data suggest tumor heterogeneity between patients as it was also shown for other cancer types. Consequently, there is an urgent need to develop new therapies that take into account this heterogeneity and the molecular characteristics of malignant pleural mesothelioma, in particular by identifying new anti-cancer drugs targeting the molecular specificities of each malignant pleural mesothelioma. Malignant pleural mesothelioma is characterized by numerous molecular alterations at the chromosomal, genetic and epigenetic levels. Molecular classification based on gene expression profile has firstly defined two tumor groups, C1 and C2, and more recently, four groups. By integrating genetic and transcriptomic analysis, a C2 LN tumor subgroup of the C2 group has been identified and characterized. In addition to tumor heterogeneity between patients, intra-tumor heterogeneity is supported by several evidences. Most therapeutic strategies that take into account the tumor molecular characteristics have focused on targeted therapies based on mutated genes. A more appropriate strategy would be to consider better-defined tumor groups on the basis of several molecular alterations types as it has been proposed for the C2 LN subgroup. A robust definition of homogeneous tumor groups sharing common molecular characteristics is necessary for the development of effective precision medicine for malignant pleural mesothelioma., (Copyright © 2017 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results